Peter Payack Finance

BROOMFIELD, CO–(Marketwire - April 29, 2009) - OpenLogic, Inc., a provider of enterprise open source software solutions encompassing hundreds of open source packages, today announced it has extended the functionality of OpenLogic Enterprise Edition (OLEX), a comprehensive open source software governance platform that integrates open source provisioning, open source policy enforcement, online approval processes, and full tracking and audit trail of open source usage.

Used by many Fortune 500 companies and medium sized businesses, OpenLogic Exchange (OLEX) Enterprise Edition is the industry’s first Software-as-a-Service (SaaS) solution for comprehensive sourcing and governance of open source software. OLEX Enterprise Edition delivers access to the OpenLogic Certified Library as part of a comprehensive open source software governance platform. The OpenLogic Library encompasses 130,000 open source packages, including more than 500 enterprise-ready open source packages that are certified, supported and indemnified by OpenLogic.

“OLEX Enterprise Edition now provides a cradle-to-grave open source management and governance solution from download to deployment to distribution,” said Kim Weins, senior vice president of products and marketing of OpenLogic. “As more enterprises increase the use of open source software due to economic conditions — prudent enterprises are demanding cradle to grave open source governance.”

The newest version of OLEX Enterprise Edition extends the management and control of open source software by adding new functionality including:

--  Identifying open source alternatives to proprietary software to save
    money: Companies can use OpenLogic's free open source scanning tool, OSS
    Discovery, to uncover usage of proprietary software like Websphere,
    Weblogic and Oracle, and then use OLEX EE to identify lower cost open
    source alternatives.

--  Tracking intended use of open source at time of download to prevent
    legal issues before they occur: OLEX EE now lets companies require users to
    declare their planned usage of open source at the time of download. This
    enables the corporation to track the intended use of open source software
    and prevent legal issues before they occur.

--  Customizing approval processes to meet enterprise needs: OLEX EE now
    provides completely customized processes for approving the use of open
    source software. Companies can define multi-step processes with customized
    forms and automated notifications and alerts.

--  Expanded audit tool with fingerprints for more than 130,000 open
    source packages: This new release of OLEX EE includes an expanded version
    of OpenLogic's free scanning tool, OSS Discovery. OSS Discovery can detect
    open source software without requiring access to source code.

Enterprise Open Source Governance and Provisioning

Built over the past few years with input from dozens of leading Fortune 500 and mid-sized businesses, OLEX Enterprise Edition is the industry’s most comprehensive governance and provision open source solution offering:

 -- Policy Management Workspace -- Allows administrators to control open
    source usage across the enterprise by specifying policies for each
    open source license and open source package. Technical and legal
    staff can see a company's policy for each open source package as
    they browse the OpenLogic Certified Library in OLEX Enterprise
    Edition, enabling them to select packages that meet their open
    source policy as well as their technical needs.
 -- API Access to the Certified Library -- Allows for RESTful or
    SOAP-based programmatic access to the Certified Library, enabling the
    creation of mash-ups and custom user interfaces.
 -- The OpenLogic Maven Repository -- Provides access to certified open
    source components using the Maven build tool.
 -- Request Approval Work Flow -- Provides an easy-to-use, web-based
    approval process that streamlines requests to use open source software
    in internal projects. It automates the approval workflow and enables
    enterprises to control the required levels of review, including
    business, legal, and technical. The Approval Manager includes email
    notifications to ensure that all of those involved in the process can
    stay abreast of status and progress.
 -- Role-Based Access -- Allows enterprises to customize OLEX Enterprise
    Edition to the way their business functions. Access to management and
    administration features is restricted by role, and roles define the
    business, legal, and technical personnel that are required to approve
    open source usage requests.
 -- OpenLogic Technical Support Portal -- Provides package-specific
    details on the technical support Service Level Agreements that have
    been purchased from OpenLogic. The Technical Support Portal also
    allows OLEX Enterprise Edition users to open new support tickets
    without picking up a telephone. Both developer support and production
    support coverage are available for the hundreds of open source
    packages in the OpenLogic Certified Library.
 -- OpenUpdate Notifications -- Delivers email alerts on security patches
    and new releases for the open source packages in the Certified
    Library.
 -- Activity Reports -- Creates transparency around the open source
    software used in the enterprise by providing tracking information on
    downloads from OLEX Enterprise Edition. These detailed reports help
    administrators monitor download activity and trends in open source
    usage across the enterprise. Reports track a variety of information on
    downloads, including:
    -- Package names and versions
    -- Who downloaded
    -- When downloads were initiated
    -- The license(s) related to the package
    -- Downloads from the Maven repository

About OpenLogic

OpenLogic is a leading provider of open source solutions that enable enterprises to safely acquire, support, and control open source software. OpenLogic provides enterprises with a certified library of open source software that encompasses hundreds of the most popular open source packages via OpenLogic Exchange (OLEX), a free web site where companies can find, research, and download certified, enterprise-ready open source packages on demand. With the broadest open source coverage in the industry, OpenLogic offers indemnification; updates; and enterprise-grade technical support backed by the OpenLogic Expert Community. OpenLogic also provides solutions for open source governance and to automate the integration and deployment of open source components — reducing the risk and maximizing the cost savings associated with using open source software. For more on OpenLogic, go to www.openlogic.com.

SAN JOSE, CA–(Marketwire - April 29, 2009) - Callidus Software Inc. (NASDAQ: CALD), the leader in Sales Performance Management (SPM), today launched the Callidus Monaco Suite: a robust, SaaS offering that delivers the most modern-looking and rich user interface experience available in the sales performance management marketplace today. The Callidus Monaco Suite is the only unified SPM software solution that provides complete alignment of the entire business with corporate objectives to optimize performance, streamline profitability and deliver a rapid ROI. The innovative offering reinforces Callidus’ lead role in the development of ground-breaking solutions that set the pace in the booming SPM arena, while further expanding its Pervasive Performance Management portfolio.

“Callidus unveiled a beautiful new user interface today. It’s clean and succinct but powerful with many layers of detail,” said Denis Pombriant, founder and managing principal at Beagle Research. “Users should be delighted with this new capability to get at sales compensation data quickly from a single screen.”

The Monaco Suite is Callidus Software’s market-leading, multi-tenant SPM offering and is available through Callidus On-Demand. The web-based solution streamlines:

– Objective Management

– Quota Management

– Reporting and Analytics

– Compensation Calculation

– Embedded Workflow

– Plan Distribution

“Issues around system usability and accessibility to essential data are increasingly being raised by companies pursuing SPM product evaluations and upgrades,” says Michael Dunne, research vice president at Gartner. “They are interested in helping business users become more self-reliant in taking advantage of application features to promote individual productivity and decrease requirements for training and IT support. Embracing interface design principles popularized by consumer Web sites is viewed as one avenue for accomplishing this, even with relatively sophisticated functions, like defining, managing, and updating plans, or delivering dashboards and reports that materially increase visibility into performance and cost trends.”

The Monaco Suite delivers all the power of a desktop application via a browser. It is easy to use and encompasses full, interactive web standards plus state-of-the-art Adobe Flash technology.

“The Monaco release is a major achievement for Callidus Software and its customers. It combines high performance, industry-leading functionality and usability,” says Leslie Stretch, president and CEO at Callidus Software. “Callidus Monaco leapfrogs all of our competitors and addresses the needs of all key market segments. The software extends our product leadership, is simple to use and implement and easy to acquire.”

With the added element of self-service capabilities, Monaco empowers the non-administrative user to make sound business decisions and adapt the solution to their specific needs. The suite’s global homepage provides striking, interactive analytical dashboards, a universal work queue and self-guided information that is most relevant to the desired actions, including the ability to:

– Establish and distribute objectives throughout organizations

– Set and distribute quota targets

– Distribute and approve compensation plans

The Monaco Suite is the most revolutionary SPM offering ever developed by Callidus. It provides the user with an end-to-end application for improving sales and employee effectiveness through the alignment of each individual’s objectives with corporate strategy. It combines proven SPM functionality that today powers the performance of more than 1.9 million sales people with goal and objective management functionality designed for the rest of the business. Until now, organizations were forced to use different systems across the enterprise for everything from appraisals and bonuses to sales force compensation, which made the task of coordinating corporate strategies complex. With the Callidus Monaco Suite, the ability to coordinate and set effective incentive programs across an entire business is seamless, thus generating quick ROI and driving revenue.

About Callidus Software®

Callidus Software (www.callidussoftware.com) (NASDAQ: CALD) is the market and technology leader in Sales Performance Management (SPM). Performance-based compensation is one of the largest investments for all companies. Callidus’ customers gain a competitive advantage by maximizing the return on this strategic asset. Our award-winning Software-as-a-Service (SaaS) applications set the standard for pervasive performance management across the enterprise. Over 1.9 million employees and channel partners have their performance managed by Callidus Software.

© 1998-2009 Callidus Software Inc. All rights reserved. Callidus Software, the Callidus Software logo, Callidus TrueAnalytics, TrueComp, TrueComp Grid, TrueComp Manager, TrueConnection, TrueFoundation, TrueInformation, TruePerformance, TruePerformance Index, TruePerformance Indicator, TrueMBO, TrueAllocation, TrueProducer, TrueQuota, TrueReferral, TrueResolution, TrueTarget and TrueService+ are trademarks, servicemarks, or registered trademarks of Callidus Software Inc. in the United States and other countries. All other brand, service or product names are trademarks or registered trademarks of their respective companies or owners.

GENEVA, SWITZERLAND–(Marketwire - April 29, 2009) - HE-5 Resources, Corp. (PINKSHEETS:HRRN) announced today, the Company name change to TRADING BARTER CORPORATION.
The Company Will File Updated Disclosure Statements

The filing for name change is being completed following the acquisition of the Trading Barter Bank exchange platform. The Corporation has been preparing for its new flagship enterprise project to kick off by the implementation of a new Corporate domicile in New York City where the first unit and corporate operations will be established through licensing structure of micro cap business model.

Management has completed the restructuring of the Company instigated in fall 2008 by proceeding to the Corporation’s recapitalization based on the “Quasi-Reorganisation” accounting rule, consisting of liquidation and dispositions of assets and liabilities including lease cancellation, payable notes, etc, having for principal objective to render the Corporation to a debt and asset free status. The exercise allows the Company to proceed to the transfer of the new intellectual property on a fresh opening statement and new solid bases.

Meanwhile our interim financial officers responsible for the reorganization program have prepared all requisite filing documentation to set up for new management appointment in preparation for other strategic acquisitions and potential up listing of the “Trading Barter Corporation.”

Management will update the shareholders as filings progresses. We invite you to visit our Corporate Web site at: www.he-5resourcescorp.com

About Trading Barter Bank^TM

Trading Barter Bank^TM models ancestral commercial trading exchange system into new “state of the art” and high tech transactional platform, built and adapted exclusively to worldwide market trends. It does offering a complete new array of financial products and nontraditional trading monetary tools, introducing “Today’s New Business Trading Network People” united under the Trading Barter Bank^TM

HE-5’s new flagship project enterprise will be targeting the implementation and acquisition of micro market Barter Companies, joining/merging with the Trading Barter Bank^TM network. Several business discussions have taken place within the last 3 months and a substantial number of market agreements in North America and Europe have emerged.

The Trading Barter Bank^TM platform is a large enterprise scale transactional hub with intuitive decisional intelligent database, embedded with automated pin point advertizing and marketing search engines that automatically positions the member’s products and services in the appropriate selling or supplying category. It is designed for micro and macro market niches. Its numerous valuation and calculation features are programmed to constantly readjust its values upon market fluctuations and offers business users instant reactive access to trading with other merchants or service providers.

Our staff has built a temporary Web site for information and communication purposes, to respond and update our partners and shareholders as final steps are taken to launch our new Trading Barter Bank^TM online platform.

Forward-Looking Statements

Please be advised that statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company’s stock price, increased competition, customer acceptance of new products and services offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating results. Please also be advised that the company’s stock is not currently registered with the Securities and Exchange Commission.

BASEL, SWITZERLAND–(Marketwire - March 31, 2009) - Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces the submission of a Marketing Authorization Application (MAA) for Toctino® (alitretinoin) in 13 additional European Union (EU) Member States as well as in Norway and Iceland. Toctino® is a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids.

The MAA for Toctino® was submitted under the Repeat Use Procedure to various EU Member States and European countries and supports the proposed use of oral alitretinoin in adults with severe chronic hand eczema that is unresponsive to potent topical corticosteroids.

“It is important for us to make Toctino available across Europe for physicians to treat patients with this chronic debilitating disease. Our submission in 15 additional European countries is a key step towards this goal,” said Dr. Anthony Man, CEO Basilea Pharmaceutica Ltd. “Furthermore, pending local approval of this second wave of Marketing Authorization Applications, we are exploring options for third-party distribution of this innovative medicine in some of these countries.”

Chronic hand eczema - a debilitating skin disease

Hand eczema is a common inflammatory skin disease and is often chronic and relapsing. Hand eczema is reported to affect up to ten percent of the general population. The more severe, chronic form of the condition is thought to affect five to seven percent of these patients, causing impaired use of their hands and a considerable impact on their ability to perform everyday activities.

Toctino® (alitretinoin), the only therapy approved for severe chronic hand eczema unresponsive to potent topical corticosteroids

Toctino® was developed by Basilea Pharmaceutica International Ltd. To date, Toctino® is launched in Denmark, Germany and the United Kingdom, and has received marketing authorization in Austria, Belgium, Finland, France and Luxemburg. In addition, Toctino® has been recommended for approval in three additional EU Member States and is under regulatory review in Switzerland and Canada.

In the largest ever phase III clinical trial program in CHE, Toctino® was the first treatment to show effective clearing of severe CHE, with clear or almost clear hands achieved in nearly 50 percent of patients treated 30 mg Toctino®. The once-daily oral therapy is given for 12 to 24 weeks, depending on patient response, and six-month post-treatment observations in patients who responded to Toctino® indicate that treatment can provide long periods free from relapse and improve patient satisfaction.

Toctino® is a known teratogen (a substance that can cause birth defects when women are exposed during pregnancy). Strict pregnancy prevention one month before, during, and one month after cessation of treatment as well as monthly pregnancy testing are required for women of childbearing age. A comprehensive pregnancy prevention program for Toctino® has been developed and implemented.

In clinical trials, Toctino® was well tolerated and demonstrated a safety profile overall consistent with the retinoid class. Overall, the most frequently reported adverse events in the phase III clinical trials were headache and increased levels of blood lipids. Side effects were dose-dependent.

A phase III clinical trial on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SWISS: BSLN). Basilea’s integrated research and development operations are currently focused on new antibacterial, antifungal and oncology agents to fight drug resistance and on the development of dermatology drugs. Basilea’s products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio including two commercialized drugs (alitretinoin, ceftobiprole) and one investigational drug in phase III (isavuconazole). Toctino® (alitretinoin) is marketed in the United Kingdom, Denmark and Germany and is approved in Austria, Belgium, Finland, France and Luxemburg. Alitretinoin has been recommended for approval in three additional EU Member States and is under regulatory review in Canada and Switzerland. Furthermore a phase III clinical trial on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S. Ceftobiprole is marketed in Canada under the brand name ZEFTERA™ and in Switzerland under Zevtera™. Marketing applications for ceftobiprole were submitted in the U.S., the EU and several other countries. The company has set up commercial organizations in UK, Denmark, Germany and Canada, while it is building sales and marketing organizations in other countries to commercialize alitretinoin and to co-promote ceftobiprole, subject to approval.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:

+-------------------------------------------------------------------+
| Media Relations                  | Investor Relations             |
|----------------------------------+--------------------------------|
| Jean-Christophe Britt, Ph.D.     | Barbara Zink, Ph.D., MBA       |
| Corporate Communication & Public | Head Corporate Development     |
| Relations                        | +41 61 606 1233                |
| +41 61 606 1354                  | investor_relations@basilea.com |
| media_relations@basilea.com      |                                |
+——————————————————————-+

This press release can be downloaded from www.basilea.com
The press release can also be downloaded from the following link:

Press release (PDF) : http://hugin.info/134390/R/1301794/297717.pdf

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.